Liquiritin Attenuates Pathological Cardiac Hypertrophy by Activating the PKA/LKB1/AMPK Pathway.

Aiyasiding, Xiahenazi; Liao, Hai-Han; Feng, Hong; Zhang, Nan; Lin, Zheng; Ding, Wen; Yan, Han; Zhou, Zi-Ying; Tang, Qi-Zhu

Aiyasiding, Xiahenazi; Liao, Hai-Han; Feng, Hong; Zhang, Nan; Lin, Zheng; Ding, Wen; Yan, Han; Zhou, Zi-Ying; Tang, Qi-Zhu.

Afiliação

Aiyasiding X; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Liao HH; Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, China.
Feng H; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Zhang N; Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, China.
Lin Z; Department of Geriatrics, Renmin Hospital of Wuhan University, Wuhan, China.
Ding W; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Yan H; Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, China.
Zhou ZY; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Tang QZ; Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, China.

Front Pharmacol ; 13: 870699, 2022.

Article em En | MEDLINE | ID: mdl-35592411

Palavras-chave

AMPKα2; PKA; cAMP; cardiac hypertrophy; heart; liquiritin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google